Exact Sciences (NASDAQ: EXAS) reported Q2 EPS of ($0.58), $0.05 better than the analyst estimate of ($0.63). Revenue for the quarter came in at $268.9 million versus the consensus estimate of $228.42 million.

For earnings history and earnings-related data on Exact Sciences (EXAS) click here.